- Home
- Publications
- Publication Search
- Publication Details
Title
Combinatorial immunotherapy for melanoma
Authors
Keywords
-
Journal
CANCER GENE THERAPY
Volume 24, Issue 3, Pages 141-147
Publisher
Springer Nature
Online
2016-11-11
DOI
10.1038/cgt.2016.56
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
- (2016) M Thorn et al. CANCER GENE THERAPY
- Targeting human melanoma neoantigens by T cell receptor gene therapy
- (2016) Matthias Leisegang et al. JOURNAL OF CLINICAL INVESTIGATION
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment patterns of adjuvant interferon-α2b for high-risk melanoma
- (2016) Enrique Espinosa et al. MELANOMA RESEARCH
- Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
- (2016) Deborah Kuk et al. ONCOLOGIST
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
- (2014) Donald L. Morton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas
- (2014) Nancy E. Thomas et al. JAMA Dermatology
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors
- (2013) Willem W Overwijk et al. Journal for ImmunoTherapy of Cancer
- Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I)
- (2012) J. Harrison Howard et al. ANNALS OF SURGICAL ONCOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Radiation Therapy to Convert the Tumor Into an In Situ Vaccine
- (2012) Silvia C. Formenti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-18 Induces PD-1-Dependent Immunosuppression in Cancer
- (2011) M. Terme et al. CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Improved Survival for Stage IV Melanoma From an Unknown Primary Site
- (2009) Chris C. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival After Lymphadenectomy for Nodal Metastasis From an Unknown Primary Melanoma
- (2008) Chris C. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation